leisure time -WSS

leisure time

author：fashion 2025-10-01 00:57:36 - browse：3274

Boxes of Ozempic photo illustration. -- health coverage from STAT — Mario Tama/Getty Images

LONDON — Novo Nordisk’s diabetes medication Ozempic cut the risk of patients developing advanced kidney disease or dying from kidney or heart complications, the company said Tuesday, adding to the evidence the wildly popular drug has broader health benefits for patients beyond addressing their diabetes.

Overall, Ozempic lowered the risk of progression of patients’ kidney disease and of related health events by 24% versus placebo, according to the topline results. The company, which will present full data from the study later this year, said it would file for an expanded approval of Ozempic based on the data in both the U.S. and Europe.

The positive announcement had been expected since October, when Novo announced it was ending the FLOW trial early because an interim data analysis showed the drug was surpassing the study’s goals. Still, the results provide an important data point for Novo both as its medicines face increasing competition and as it tries to get more insurers to cover its related obesity drug Wegovy.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Russian fighter jet damages US Reaper drone with flare over Syria: Officials

hotspot

focus

explore

WSS

Bronny James, LeBron's son, suffers cardiac arrest during basketball practice at USC

'Investigate these claims': UFO transparency at center of House hearing

What causes rare myocarditis in young men after Covid vaccines?

New study raises questions about niacin and heart health

MD Anderson's Padmanee Sharma responds to research credit suit

Former reverend arrested for allegedly killing 8

explore

leisure time

focus

Psychedelics group wrestles with new pharma identity

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Moonlake's readout produced a cash windfall. Risks remain

Measles policy set amid Florida outbreak alarms vaccine proponents

Medicare details structure of new drug price negotiation program

CDC Director Mandy Cohen on transparency, trust, and health

As demand for Covid shots wanes, Moderna seeks its next success

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Affirmative action in medical school literally saved lives

As AI regulations shape up, health tech startups beg for clarity

entertainment

Hospitals are piloting generative AI tools as regulators play catch

In the gardens at Boston Children's Hospital, families find sanctuary

Opioid cravings were reduced by anti

UHS says company favors patients whose insurance pays more

New lawsuit accuses health insurer Cigna of denying claims in bulk

Measles policy set amid Florida outbreak alarms vaccine proponents

hotspot

focus

explore

leisure time